Registry for patients with advanced rare cancers in Asia

A Prospective Clinical Registry Study of Genetic Profiling and Targeted Therapies in Patients With Rare Cancers in ASIA

This study is collecting information from patients with advanced rare cancers in Asia to see how different treatments work and to find better, personalized options for their care.

Quick facts

• Study type: Observational
• Enrollment: 1000 (estimated)
• Ages: 18 Years and up
• Sex: All
• Sponsor: National Cancer Center, Japan (Government)
• Locations: 18 sites (Chuo-ku, Tokyo and 17 other locations)
• Trial ID: NCT05217407 on ClinicalTrials.gov

What this trial studies

This observational registry study aims to collect comprehensive data from patients diagnosed with advanced-stage rare cancers in the Asia-Pacific region. It will gather clinical information, treatment details, prognosis, pathological diagnoses, and genetic biomarkers through next-generation sequencing. The study seeks to explore the relationships between different cancer types, treatment effects, and the incidence of genomic alterations to identify more effective, tailored treatment options for these rare malignancies.

Who should consider this trial

Good fit: Ideal candidates include patients with a histological diagnosis of rare cancer or advanced-stage cancer.

Not a fit: Patients with cognitive impairments or those not diagnosed with rare cancers may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could lead to more personalized and effective treatment strategies for patients with rare cancers.

How similar studies have performed: Other studies focusing on genomic alterations in rare cancers have shown promise, suggesting that this approach could yield valuable insights.

Eligibility criteria

Inclusion Criteria:

1. Patients with a histological diagnosis of rare cancer, cancer of unknown primary origin, or cancer of rare tissue subtypes of common cancers. (Defined in protocol.)
2. Patients with Advanced stage cancer.

Exclusion Criteria:

1\. Patients with complications of cognitive impairment.

Where this trial is running

Chuo-ku, Tokyo and 17 other locations

• National Cancer Center Hospital, Japan — Chuo-ku, Tokyo, Japan (Recruiting)
• Hospital Sultan Ismail — Johor Bahru, Johor, Malaysia (Recruiting)
• Hospital Pulau Pinang — Pulau Pinang, Pulau Pinang, Malaysia (Recruiting)
• Sarawak General Hospital — Kuching, Sarawak, Malaysia (Recruiting)
• Hospital Kuala Lumpur — Kuala Lumpur, Malaysia (Recruiting)
• University Malaya Medical Center — Kuala Lumpur, Malaysia (Recruiting)
• Institut Kanser negara — Putrajaya, Malaysia (Recruiting)
• St. Luke's Medical Center — Manila, Philippines (Recruiting)
• National Cancer Center Korea — Seoul, South Korea (Recruiting)
• National Taiwan University Hospital — Taipei, Zhongzheng, Taiwan (Recruiting)
• Taipei Veterans General Hospital — Taipei, Taiwan (Recruiting)
• Mahidol University by Faculty of Medicine, Ramathibodi Hospita — Bangkok, Thailand (Recruiting)
• Mahidol University by Faculty of Medicine, Siriraj Hospital — Bangkok, Thailand (Recruiting)
• Maharaj Nakorn Chiang Mai Hospital — Chiang Mai, Thailand (Not_yet_recruiting)
• Faculty of Medicine, Prince of Songkla University — Hat Yai, Thailand (Recruiting)
• Khon Kaen University by Faculty of Medicine, Srinagarind Hospital — Khon Kaen, Thailand (Recruiting)
• National Cancer Vietnam — Hanoi, Vietnam (Recruiting)
• Ho Chi Minh City Oncology Hospital — Ho Chi Minh City, Vietnam (Not_yet_recruiting)

Study contacts

• Principal investigator: Noboru Yamamoro, MD, PhD — National Cancer Center Hospital, Japan
• Study coordinator: Chiharu Mizoguchi, MD

Conditions Rare Malignant Neoplasm; Rare cancer; Rare subtype; Registry; Asia; Next-generation sequencing